Lumoxiti

Active Ingredient(s): Moxetumomab Pasudotox-tdfk
FDA Approved: * September 13, 2018
Pharm Company: * ASTRAZENECA AB
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lumoxiti Overview

Moxetumomab pasudotox is an anti-CD22 immunotoxin designed for the treatment of cancer.[1] Moxetumomab pasudotox is currently being developed by the biologics division of AstraZeneca, MedImmune. On 16 May 2013, the first dose in a Phase III trial was administered.[2][3] In Sept 2018 the US FDA approved it (as Lumoxiti) for some cases of relapsed or refractory hairy cell leukemia (HCL).[4] Discovery and Ownership Background On ...

Read more Lumoxiti Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Moxetumomab_pasudotox

Recent Lumoxiti Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lumoxiti: (1 result)

Sorted by National Drug Code

• 0310-4700 Lumoxiti 1 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Moxetumomab Pasudotox-tdfk or a similar ingredient: (1 result)

• MOXETUMOMAB PASUDOTOX